NASDAQ:RPHM Reneo Pharmaceuticals (RPHM) Stock Forecast, Price & News $8.18 -0.35 (-4.10%) (As of 06/2/2023 06:55 PM ET) Add Compare Share Share Today's Range$8.00▼$8.7250-Day Range$5.42▼$10.5052-Week Range$1.79▼$11.30Volume76,900 shsAverage Volume83,286 shsMarket Capitalization$275.30 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Reneo Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside242.3% Upside$28.00 Price TargetShort InterestHealthy2.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.84Based on 2 Articles This WeekInsider TradingAcquiring Shares$1 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.31) to ($2.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector134th out of 980 stocksPharmaceutical Preparations Industry55th out of 485 stocks 3.5 Analyst's Opinion Consensus RatingReneo Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Reneo Pharmaceuticals has a forecasted upside of 242.3% from its current price of $8.18.Amount of Analyst CoverageReneo Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.34% of the float of Reneo Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverReneo Pharmaceuticals has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Reneo Pharmaceuticals has recently increased by 121.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldReneo Pharmaceuticals does not currently pay a dividend.Dividend GrowthReneo Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPHM. Previous Next 3.2 News and Social Media Coverage News SentimentReneo Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Reneo Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for RPHM on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows2 people have added Reneo Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reneo Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.90% of the stock of Reneo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.61% of the stock of Reneo Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reneo Pharmaceuticals are expected to grow in the coming year, from ($2.31) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reneo Pharmaceuticals is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reneo Pharmaceuticals is -3.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReneo Pharmaceuticals has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Reneo Pharmaceuticals (NASDAQ:RPHM) StockReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. The company was incorporated in 2014 and is headquartered in Irvine, California.Read More Receive RPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reneo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RPHM Stock News HeadlinesMay 31, 2023 | finance.yahoo.comUpdate -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare ConferenceMay 31, 2023 | finance.yahoo.comReneo Pharmaceuticals to Participate at the Jefferies Healthcare ConferenceJune 5, 2023 | Edge On The Street (Ad)Investor Alert: EV Initiatives Create Unsustainable Demand For LithiumThe soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.May 26, 2023 | seekingalpha.comRPHM Reneo Pharmaceuticals, Inc.May 21, 2023 | finance.yahoo.comInsiders Pour $1 Million Each Into These 2 ‘Strong Buy’ Stocks — Here’s Why Wall Street Thinks They Could Double (or More)May 11, 2023 | msn.comReneo Pharmaceuticals: Q1 Earnings InsightsMay 11, 2023 | finanznachrichten.deReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comReneo Pharmaceuticals Reports First Quarter 2023 Financial ResultsJune 5, 2023 | Edge On The Street (Ad)Investor Alert: EV Initiatives Create Unsustainable Demand For LithiumThe soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.May 9, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Reneo Pharmaceuticals (RPHM)May 4, 2023 | marketwatch.comReneo Pharma Shares Drop 21% After $55M Public Offering PricesMay 4, 2023 | finance.yahoo.comReneo Announces Pricing of Public Offering of Common StockMay 3, 2023 | msn.comReneo Pharmaceuticals launches stock offering, shares fall 10%May 3, 2023 | finance.yahoo.comReneo Pharmaceuticals Announces Proposed Public Offering of Common StockApril 5, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Reneo Pharmaceuticals (RPHM)April 1, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Reneo Pharmaceuticals, Inc. Cut by Jefferies Financial Group (NASDAQ:RPHM)March 29, 2023 | americanbankingnews.comReneo Pharmaceuticals (NASDAQ:RPHM) Announces Earnings ResultsMarch 27, 2023 | finanznachrichten.deReneo Pharmaceuticals, Inc.: Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 27, 2023 | finance.yahoo.comReneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 14, 2023 | finance.yahoo.comReneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial MyopathiesMarch 9, 2023 | finance.yahoo.comReneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023March 3, 2023 | finance.yahoo.comReneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) largest shareholders are private equity firms who were rewarded as market cap surged US$33m last weekFebruary 2, 2023 | finance.yahoo.comReneo Pharmaceuticals to Participate in SVB Securities Global Biopharma ConferenceJanuary 31, 2023 | finance.yahoo.comReneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)December 4, 2022 | finance.yahoo.comIs Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?November 8, 2022 | finance.yahoo.comReneo Pharmaceuticals Reports Third Quarter 2022 Financial ResultsSeptember 19, 2022 | nasdaq.comIndividual investors own 22% of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) shares but private equity firms control 60% of the companySee More Headlines RPHM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPHM Company Calendar Last Earnings3/27/2023Today6/04/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RPHM CUSIPN/A CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployees24Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.00 High Stock Price Forecast$31.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+242.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.06% Return on Assets-46.66% Debt Debt-to-Equity RatioN/A Current Ratio9.26 Quick Ratio9.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.59 per share Price / Book3.16Miscellaneous Outstanding Shares33,650,000Free Float27,631,000Market Cap$275.26 million OptionableNot Optionable Beta1.24 Key ExecutivesMr. Michael G. Grey (Age 69)Founder & Exec. Chairman Mr. Gregory J. Flesher (Age 52)Pres, CEO & Director Comp: $743.05kMr. Michael P. Cruse (Age 50)Chief Operating Officer Comp: $423.3kMr. Vineet R. Jindal (Age 44)Consultant Comp: $568.27kMs. Jennifer P. LamPrincipal Financial & Accounting OfficerMs. Wendy S. Johnson M.B.A. (Age 70)Consultant Dr. Alejandro Dorenbaum M.D. (Age 61)Chief Medical Officer Ms. Lynn Purkins Ph.D.Sr. VP of Clinical OperationsMs. Ashley F. Hall J.D. (Age 50)Chief Devel. Officer More ExecutivesKey CompetitorsALX OncologyNASDAQ:ALXOAcrivon TherapeuticsNASDAQ:ACRVGeneration BioNASDAQ:GBIONuvectis PharmaNASDAQ:NVCTFoghorn TherapeuticsNASDAQ:FHTXView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 14,800 shares on 6/1/2023Ownership: 0.044%Great Point Partners LLCBought 120,864 shares on 5/16/2023Ownership: 0.481%Geode Capital Management LLCBought 8,297 shares on 5/16/2023Ownership: 0.385%Susquehanna International Group LLPBought 32,358 shares on 5/16/2023Ownership: 0.129%Jane Street Group LLCBought 19,743 shares on 5/16/2023Ownership: 0.079%View All Insider TransactionsView All Institutional Transactions RPHM Stock - Frequently Asked Questions Should I buy or sell Reneo Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reneo Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPHM shares. View RPHM analyst ratings or view top-rated stocks. What is Reneo Pharmaceuticals' stock price forecast for 2023? 2 brokerages have issued 12-month price objectives for Reneo Pharmaceuticals' stock. Their RPHM share price forecasts range from $25.00 to $31.00. On average, they expect the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 242.3% from the stock's current price. View analysts price targets for RPHM or view top-rated stocks among Wall Street analysts. How have RPHM shares performed in 2023? Reneo Pharmaceuticals' stock was trading at $2.33 at the beginning of 2023. Since then, RPHM shares have increased by 251.1% and is now trading at $8.18. View the best growth stocks for 2023 here. Are investors shorting Reneo Pharmaceuticals? Reneo Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 255,600 shares, an increase of 121.1% from the April 30th total of 115,600 shares. Based on an average daily volume of 107,500 shares, the days-to-cover ratio is currently 2.4 days. Approximately 2.3% of the shares of the company are short sold. View Reneo Pharmaceuticals' Short Interest. When is Reneo Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our RPHM earnings forecast. How were Reneo Pharmaceuticals' earnings last quarter? Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) released its quarterly earnings data on Monday, March, 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.03. When did Reneo Pharmaceuticals IPO? (RPHM) raised $101 million in an IPO on Friday, April 9th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. What is Reneo Pharmaceuticals' stock symbol? Reneo Pharmaceuticals trades on the NASDAQ under the ticker symbol "RPHM." Who are Reneo Pharmaceuticals' major shareholders? Reneo Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Carlyle Group Inc. (8.26%), ExodusPoint Capital Management LP (0.98%), Great Point Partners LLC (0.48%), Geode Capital Management LLC (0.38%), Federated Hermes Inc. (0.31%) and MAI Capital Management (0.21%). Insiders that own company stock include Bali Muralidhar, Gregory J Flesher, Holdings A/S Novo, Michael Cruse, Niall O'donnell, Venture Fund Iii L Rivervest and Vineet R Jindal. View institutional ownership trends. How do I buy shares of Reneo Pharmaceuticals? Shares of RPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Reneo Pharmaceuticals' stock price today? One share of RPHM stock can currently be purchased for approximately $8.18. How much money does Reneo Pharmaceuticals make? Reneo Pharmaceuticals (NASDAQ:RPHM) has a market capitalization of $275.26 million. The company earns $-51,960,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. How can I contact Reneo Pharmaceuticals? The official website for the company is reneopharma.com. The company can be reached via phone at 858-283-0280 or via email at investors@reneopharma.com. This page (NASDAQ:RPHM) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reneo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.